Table 5.
Clinical data for treatment of LAUPC using X-ray therapy plus a chemotherapy cocktail including gemcitabine.
| Reference | Year | Total dose (Gy) | Fractions | Chemotherapy | Sample size | 1 year OS | 2 years OS | Median OS |
|---|---|---|---|---|---|---|---|---|
| Chung et al. (82) | 2004 | 45 | 25 | Gem 1000 mg/m2 weekly + Doxifluoridine 600 mg/m2 daily during and after RT | 22 | 50% | N/A | 12 |
| Haddock et al. (83) | 2007 | 45 | 25 | Gem 30 mg/m2 + Cisplatin 10 mg/m2 twice weekly during first 3 weeks of RT, Gem 1000 mg/m2 weekly after RT | 48 | 40% | N/A | 10.2 |
| Hong et al. (84) | 2008 | 45 | 25 | Gem 1000 mg/m2 weekly + Cisplatin 70 mg/m2 two times during RT, maintenance Gem 1000 mg/m2 weekly + Cisplatin 70 mg/m2 every 4 weeks | 38 | 63.3% | 27.9% | 16.7 |
| Mamon et al. (85) | 2011 | 50.4 | 28 | Gem 200 mg/m2 weekly + 5-FU 200 mg/m2 5 days/week during RT, maintenance Gem 1000 mg/m2 weekly | 78 | 51% | N/A | 12.2 |
| Crane et al. (86) | 2011 | 50.4 | 28 | Gem 1000 mg/m2 + Oxaliplatin 100 mg/m2 before RT + Capecitabine 825 mg/m2 twice daily on RT days, cetuximab 500 mg/m2 every 2 weeks before and during RT | 69 | 66% | 25% | 19.2 |
| Brunner et al. (74) | 2011 | 55.8 | 31 | Gem 300 mg/m2 + Cisplatin 30 mg/m2 weekly during RT | 58 | 53% | N/A | 12.7 |
| Ch’Ang et al. (87) | 2011 | 50.4 | 28 | Gem 800 mg/m2 + Oxaliplatin 85 mg/m2 + 5-FU/Leucovorin 3000/150 mg/m2 twice/week before RT, Gem 400 mg/m2 weekly during RT | 50 | 68% | 20.6% | 14.5 |
| Tozzi et al. (88) | 2013 | 45 | 6 | Gem-based before RT | 30 | 47% | N/A | 11 |
| Ke et al. (89) | 2014 | 50.4 | 28 | Gem 1000 mg/m2 weekly + S-1 40 mg/m2 twice daily before RT, S-1 80 mg/m2 twice daily during RT, S-1 80 mg/m2 twice daily 1 month after RT | 32 | 75% | 34.4% | 15.2 |
| Wang et al. (42) | 2015 | 46 | 23 | Gem-based (sub-groups) | 16 | 71.1% | 40.6% | 19.5 |